In this issue of Cell, Gusarova et al. (2014) show that deletion of ANGPTL8 in mice does not affect the compensatory proliferation of pancreatic beta cells in response to insulin resistance induced by a high-fat diet or treatment with the insulin antagonist S961. They also show that overexpression of human ANGPTL8 in mouse liver leads to elevated serum triglyceride levels but not significant pancreatic beta cell proliferation. They conclude that ANGPTL8 (also called betatrophin [Yi et al., 2013] /RIFL [Ren et al., 2012] /lipasin [Zhang, 2012] ) does not control pancreatic beta cell expansion. Their experimental design and data are clearly presented and straightforward, and we agree with their conclusions. Our own follow-up experiments using an independent knockout of ANGPTL8 produced the same result. Taken together, these new data contradict our previous conclusion (Yi et al., 2013) that betatrophin is the sole agent responsible for beta cell proliferation following S961 treatment. Furthermore, these new results cast doubt on the finding that beta cell proliferation can be induced by overexpression of ANGPTL8/ betatrophin.
The work presented in Yi et al. (2013) had at its foundation the finding that the insulin antagonist S961 causes a specific and robust increase in beta cell proliferation and subsequently beta cell mass. This finding has now been reproduced by Kaestner's group (Jiao et al., 2014) and Gusarova et al. However, additional experiments by our lab ( Figure 1A ) and those by Gusarova et al. (Gusarova et al., 2014; Figures 2F and S1 ) using tail vein injection to overexpress ANGPTL8/ betatrophin show a significant and unsatisfactory variation, perhaps as a result of liver inflammation, which makes it difficult to draw a secure conclusion about beta cell replication. In Yi et al. we reported an average beta cell replication rate of 4% in betatrophin-injected mice (n = 7); with five additional experiments (n = 52 mice in total), the average beta cell replication rate in betatrophin-injected mice drops to 1.2%. While still significantly above control levels (p = 0.016 for all experiments) of beta cell replication (0.6%), the conclusion from Yi et al. must be corrected and modified with respect to the magnitude of the effect. A confounding issue is that these injection experiments show a ''jackpot'' effect on beta cell replication ( Figures 1A and 1B) ; some mice respond strongly to ANGPTL8/betatrophin expression but many do not. When all mice are taken into account (three experiments in Yi et al. [Yi et al., 2013] , five new experiments here in Figure 1A , and Gusarova et al. [Gusarova et al. 2014]) , and compared to control injected animals, the results show a modest average increase in beta cell replication.
In all, the variation in beta cell replication following tail vein injection with DNA should either be ignored because it is an artifact or further pursued as a clue to the numerous and complex functions of the ANGPTL gene family. With respect to the latter, one possibility is that ANGPTL8 requires a binding partner that can be induced by tail vein injection. Of interest in this regard is ANGPTL3, which is structurally similar to ANGPTL8 and is located in the intron of a Dock gene as is ANGPTL8. Moreover, deletion or overexpression of ANGPTL3 and ANGPTL8 have similar effects on serum triglycerides (Quagliarini et al., 2012; Santulli, 2014) . Hobbs and colleagues have previously shown that these Angptl proteins exist in large complexes and demonstrated that these proteins regulate serum triglycerides (Quagliarini et al., 2012) . We find similar results with respect to the large protein complexes ( Figure 1C ) consistent (B) The data from our original report (Yi et al., 2013, Figure S3F ) is replotted in the same format. (C) Human serum fractionated in a nondenaturing gel stained with anti-hBetatrophin antibody. hBetatrophin migrates as a high molecular weight (480-1,000 kDa) complex compared to recombinant hBetatrophin protein (60-100 kDa. Phoenix Pharmaceuticals).
with the notion that the members of this family do not act alone. Together these data suggest to us that further analysis of whether and how members of the Angptl family interact, perhaps having redundant functions, is warranted.
Another approach to investigating this issue is to find the receptor for Angptl8/ betatrophin or its protein complex and study the function of the receptor on beta cell proliferation. We have cloned two membrane proteins that bind to Angptl8/betatrophin. One, Marco, is expressed in macrophages found in the pancreas and known to regulate lipid metabolism (Perez et al., 2010) . The other receptor is RTN4R, a neuronal receptor (Fournier et al., 2001) . It is possible that Angptl8/betatrophin uses the macrophage receptor to regulate lipid/triglyceride metabolism and the neuronal receptor actually mediates the signaling to pancreatic beta cells through nerves. To date, no direct connection has been established between changes in triglycerides and beta cell replication induced by S961 treatment. It is interesting that neuronal signal has been shown to promote beta cell proliferation in insulin resistance status (Imai et al., 2008) , and the magnitude of the beta cell proliferation Imai et al. observed is very similar to some of our Angptl8/betatrophin hepatic overexpressed mice.
In summary, Gusarova et al. confirmed our original finding that the insulin receptor antagonist S961 causes dramatic pancreatic beta cell replication, thus providing an important research tool for studying beta cell proliferation. And we agree with the main conclusion of Gusarova et al., namely that deletion of Angptl8/betatrophin itself does not support the idea that betatrophin alone is a capable of inducing pancreatic beta cell proliferation. The mechanisms controlling beta cell replication are clearly more complicated than we put forth in Yi et al. (Yi et al., 2013) . The new data provided by Gusarova et al. helps clarify the emerging understanding of how members of the Angptl family effect serum triglycerides and weakens the case that there is a direct link to beta cell replication. The agents responsible for inducing beta cell replication following S961 treatment may be triglyceride levels, members of the Angptl family, or some other factor(s) yet to be identified. We are committed to solving this puzzle in mice and then move on to determine whether or not any of these findings in mice are relevant to the human condition.
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